Related references
Note: Only part of the references are listed.Terminology for Preparations of Botulinum Neurotoxins What a Difference a Name Makes
Alberto Albanese
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia
Daniel Truong et al.
PARKINSONISM & RELATED DISORDERS (2010)
Effect of Cervical Dystonia on Employment: A Retrospective Analysis of the Ability of Treatment to Restore Premorbid Employment Status
Eric S. Molho et al.
MOVEMENT DISORDERS (2009)
Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: Randomized, double-blind, noninferiority trial
Eric J. Pappert et al.
MOVEMENT DISORDERS (2008)
Cervical dystonia: Unresolved issues and future challenges
Geoffrey Sheean
NEUROLOGIC CLINICS (2008)
Epidemiology, clinical presentation, and diagnosis of cervical dystonia
Mark Stacy
NEUROLOGIC CLINICS (2008)
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
D. M. Simpson et al.
NEUROLOGY (2008)
Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia
I. M. Skogseid et al.
EUROPEAN JOURNAL OF NEUROLOGY (2007)
Prevalence of cervical dystonia and spasmodic torticollis in the United States general population
J. Jankovic et al.
PARKINSONISM & RELATED DISORDERS (2007)
CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia
S. J. Cano et al.
NEUROLOGY (2006)
Current concepts - Dystonia
Daniel Tarsy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia
CL Comella et al.
NEUROLOGY (2005)
Efficacy and safety of repeated doses of botulinum toxin type B in type a resistant and responsive cervical dystonia
SA Factor et al.
MOVEMENT DISORDERS (2005)
Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX (R)) for cervical dystonia
A Brashear et al.
ADVANCES IN THERAPY (2005)
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
RH Dworkin et al.
PAIN (2005)
Botulinum toxin in clinical practice
J Jankovic
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Capturing the true burden of dystonia on patients - The Cervical Dystonia Impact Profile (CDIP-58)
SJ Cano et al.
NEUROLOGY (2004)
Core outcome domains for chronic pain clinical trials: IMMPACT recommendations
DC Turk et al.
PAIN (2003)
Quetiapine improves involuntary movements after cerebellar stroke
T Müller et al.
JOURNAL OF NEUROLOGY (2002)
Impact of cervical dystonia on quality of life
L Camfield et al.
MOVEMENT DISORDERS (2002)
What are the determinants of quality of life in people with cervical dystonia?
Y Ben-Shlomo et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2002)
Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia
R Hilker et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2001)